In vitro activity of BMY 28100, a new oral cephalosporin
- 1 February 1987
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 6 (1) , 111-113
- https://doi.org/10.1007/bf02097214
Abstract
BMY 28100, a new oral cephalosporin, demonstrated good in vitro activity against common gram-positive and gram-negative respiratory and urinary tract pathogens. Its activity was shown by microdilution techniques to be generally higher than those of ampicillin, cephalothin and cephalexin, but comparable to those of cefaclor and, except forHaemophilus spp. andBrantiamella spp., to amoxicillin/clavulanate.Keywords
This publication has 1 reference indexed in Scilit:
- β-Lactam antibiotics: The first- and second-generation cephalosporinsAntimicrobic Newsletter, 1985